Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-28T08:57:56.550Z Has data issue: false hasContentIssue false
  • English
  • Français

Decreasing incidence of Acinetobacter baumannii pneumonia and trends in antibiotic consumption: A single-center retrospective observational study

Published online by Cambridge University Press:  13 August 2021

Andrew T. Peters Open the ORCID record for Andrew T. Peters [Opens in a new window] ,
Chiagozie I. Pickens ,
Michael J. Postelnick ,
Teresa R. Zembower ,
Chao Qi  and
Richard G. Wunderink
Andrew T. Peters*
Affiliation:
Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
Chiagozie I. Pickens
Affiliation:
Division of Pulmonary and Critical Care, Northwestern University Feinberg School of Medicine, Chicago, Illinois
Michael J. Postelnick
Affiliation:
Department of Pharmacy, Northwestern Medicine, Chicago, Illinois
Teresa R. Zembower
Affiliation:
Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois
Chao Qi
Affiliation:
Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
Richard G. Wunderink
Affiliation:
Division of Pulmonary and Critical Care, Northwestern University Feinberg School of Medicine, Chicago, Illinois
*
Author for correspondence: Andrew T. Peters, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To describe the epidemiology of Acinetobacter baumannnii (AB) pneumonia at our center, including the antibiotic exposure patterns of individual AB pneumonia cases and to investigate whether hospital-wide antibiotic consumption trends were associated with trends in AB pneumonia incidence.

Design:

Single-center retrospective study with case-control and ecological components.

Setting:

US private tertiary-care hospital.

Participants and methods:

All hospitalized patients with AB infection from 2008 to 2019 were identified through laboratory records; for those with AB pneumonia, medical records were queried for detailed characteristics and antibiotic exposures in the 30 days preceding pneumonia diagnosis. Hospital-wide antibiotic consumption data from 2015 through 2019 were obtained through pharmacy records.

Results:

Incidence of both pneumonia and nonrespiratory AB infections decreased from 2008 to 2019. Among the 175 patients with AB pneumonia, the most frequent antibiotic exposure was vancomycin (101 patients). During the 2015–2019 period when hospital-wide antibiotic consumption data were available, carbapenem consumption increased, and trends negatively correlated with those of AB pneumonia (r = −0.48; P = .031) and AB infection at any site (r = −0.63; P = .003). Conversely, the decline in AB infection at any site correlated positively with concurrent declines in vancomycin (r = 0.55; P = .012) and quinolone consumption (r = 0.51; P = .022).

Conclusions:

We observed decreasing incidence of AB infection despite concurrently increasing carbapenem consumption, possibly associated with declining vancomycin and quinolone consumption. Future research should evaluate a potential role for glycopeptide and quinolone exposure in the pathogenesis of AB infection.

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 43 , Issue 9 , September 2022 , pp. 1155 - 1161
Check for updates
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

PREVIOUS PRESENTATION. An abstract version of the findings has been presented at the American Thoracic Society International Conference, May 2021.

References

Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: US Department of Health and Human Services, CDC; 2019.Google Scholar
Antunes, LC, Visca, P, Towner, KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis 2014;71:292–301.CrossRefGoogle ScholarPubMed
Maragakis, LL, Perl, TM, Logan, LK, et al. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008;46:1254–1263.CrossRefGoogle ScholarPubMed
Peleg, AY, Seifert, H, Paterson, DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008;21:538–582.CrossRefGoogle ScholarPubMed
Logan, LK, Gandra, S, Trett, A, Weinstein, RA, Laxminarayan, R. Acinetobacter baumannii resistance trends in children in the United States, 1999–2012. J Pediatric Infect Dis Soc 2019;8:136–142.CrossRefGoogle ScholarPubMed
Falagas, ME, Kopterides, P, Perez, F, et al. Risk factors for the isolation of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006;64:7–15.CrossRefGoogle Scholar
Mah, MW, Memish, ZA, Cunningham, G, et al. Outbreak of Acinetobacter baumannii in an intensive care unit associated with tracheostomy. Am J Infect Control 2001;29:284–288.CrossRefGoogle Scholar
Perez, F, Endimiani, A, Ray, AJ, et al. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother 2010;65:1807–1818.CrossRefGoogle ScholarPubMed
Cho, OH, Bak, MH, Baek, EH, Park, KH, Kim, S, Bae, IG. Successful control of carbapenem-resistant Acinetobacter baumannii in a Korean university hospital: a 6-year perspective. Am J Infect Control 2014;42:976–979.CrossRefGoogle Scholar
Corbella, X, Montero, A, Pujol, M, et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 2000;38:4086–4095.CrossRefGoogle ScholarPubMed
Centers for Disease Control and Prevention. Antibiotic Use in the United States: Progress and Opportunities. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2017.Google Scholar
Klein, EY, Van Boeckel, TP, Martinez, EM, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci USA 2018;115:E3463–E3470.CrossRefGoogle ScholarPubMed
Paonessa, JR, Shah, RD, Pickens, CI, et al. Rapid detection of methicillin-resistant Staphylococcus aureus in BAL: a pilot randomized controlled trial. Chest 2019;155:999–1007.CrossRefGoogle ScholarPubMed
Pickens, CI, Qi, C, Postelnick, M, et al. Association between a rapid diagnostic test to detect methicillin-resistant Staphylococcus aureus pneumonia and decreased vancomycin use in a medical intensive care unit over a 30-month period. Infect Control Hosp Epidemiol 2021;71. doi: 10.1017/ice.2020.1406.CrossRefGoogle Scholar
Markoski, N, Wang, SK, Bertram, C, et al. 2010. A Significant reduction in empiric vancomycin days of therapy for suspected MRSA pneumonia in adult non-ICU patients after implementation of a rapid MRSA nasal PCR test with antimicrobial stewardship intervention. Open Forum Infect Dis 2019;6:S674–S675.CrossRefGoogle Scholar
Lim, CLL, Chua, AQ, Teo, JQM, Cai, Y, Lee, W, Kwa, AL. Importance of control groups when delineating antibiotic use as a risk factor for carbapenem resistance, extreme drug resistance, and pan-drug resistance in Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review and meta-analysis. Int J Infect Dis 2018;76:48–57.CrossRefGoogle ScholarPubMed
Microbial determinants of failure of antimicrobial therapy. Successful Clinical Response in Pneumonia Therapy (SCRIPT) website. https://script.northwestern.edu/research/project-2/. Accessed February 15, 2021.Google Scholar